Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Jun 2024
Jha stated that physicians should consider interventional strategies for treating treatment-resistant depression "sooner rather than later" in an interview with HCPLive. ".
Read Full NewsAripiprazole is associated with a lower risk for hyponatremia compared with olanzapine in patients treated with second-generation antipsychotics, a new cohort study shows.
Researchers evaluate changes in post-transplantation outcomes among patients with relapsed or refractory Hodgkin lymphoma from 2010 to 2022.
In a recent KFF survey, 43% of US adults said they had skipped their medication in the past year because of cost.
1.
Next Day Mood Is Affected by Ability to Recover From Work.
2.
Enhanced CAR T cell therapy offers new strategy for lymphoma
3.
With the use of a novel sequencing technique, pediatric bone marrow transplant mortality can be predicted by analyzing lung microbiomes.
4.
Decrease seen in in situ breast cancer since 2009
5.
Scientists hail the cervical cancer treatment as the most remarkable breakthrough in 20 years.
1.
Discovering the Benefits of TNK: A Comprehensive Blog Article
2.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
3.
Revolutionizing Cancer Treatment with Darzalex: How an Innovative Drug is Transforming Lives
4.
Personalized Cancer Vaccines: The Next Frontier in Precision Oncology
5.
Precision Medicine and Genomics: Revolutionizing Healthcare Through Personalized Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
2.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part II
3.
Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients
4.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
5.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge